巴基斯坦2018-21年抗生素耐药性调查:基于CLSI、EUCAST和PK/PD折点的数据
该研究分析了2018-21年巴基斯坦拉合尔社区获得性呼吸道感染中分离的肺炎链球菌(n=57)和流感嗜血杆菌(n=67)的药敏数据,采用CLSI微量肉汤稀释法测定MIC,并分别用CLSI、EUCAST和PK/PD折点解读。结果显示青霉素敏感肺炎链球菌比例因折点不同差异显著(28.1% vs 98.3%/98.2%),多数抗生素仍保持较好活性,但四环素类、大环内酯类和复方磺胺甲噁唑活性较差。研究强调持续药敏监测对经验性治疗的重要性。
要点
- 肺炎链球菌青霉素敏感率因折点而异:CLSI口服/EUCAST低剂量为28.1%,EUCAST高剂量/CLSI静脉为98.3%/98.2%。
- 阿莫西林、阿莫西林/克拉维酸、头孢噻肟、头孢泊肟、头孢曲松、头孢呋辛、左氧氟沙星和莫西沙星活性良好(≥93.0%)。
- 流感嗜血杆菌多数为β-内酰胺酶阴性(95.5%),除复方磺胺甲噁唑外CLSI药敏多>83.6%。
核心结论
- 尽管存在耐药,巴基斯坦社区获得性呼吸道感染中肺炎链球菌和流感嗜血杆菌仍有许多治疗选择。
- 继续监测抗生素敏感性对指导经验性治疗很重要。
研究设计与样本
- 研究纳入2018-21年巴基斯坦拉合尔Shaukat Khanum纪念癌症医院和研究中心收集的肺炎链球菌(n=57)和流感嗜血杆菌(n=67)分离株。
- 采用CLSI微量肉汤稀释法测定MIC,并用CLSI、EUCAST和PK/PD折点解读药敏。
主要发现
- 肺炎链球菌对青霉素敏感率:CLSI口服/EUCAST低剂量折点为28.1%,EUCAST高剂量/CLSI静脉折点为98.3%/98.2%。
- 用CLSI或PK/PD折点,阿莫西林、阿莫西林/克拉维酸、头孢噻肟、头孢泊肟、头孢曲松、头孢呋辛、左氧氟沙星和莫西沙星活性良好(≥93.0%)。
- 头孢地尼和头孢克洛活性较低:CLSI折点下分别为75.4%和57.9%,PK/PD折点下分别为61.4%和19.3%。
- 四环素类、大环内酯类和复方磺胺甲噁唑活性差(5.3%-36.8%)。
- 流感嗜血杆菌中95.5%为β-内酰胺酶阴性;除复方磺胺甲噁唑(13.4%)外,CLSI折点下药敏多>83.6%。
关键数值与推荐
- 肺炎链球菌青霉素敏感:CLSI口服/EUCAST低剂量28.1%,EUCAST高剂量98.2%,CLSI静脉98.3%。
- 头孢克洛EUCAST高剂量折点敏感率0%,头孢泊肟70.2%,头孢呋辛68.4%,均低于CLSI。
- 流感嗜血杆菌对头孢呋辛(口服)EUCAST敏感率0%,CLSI 95.5%,PK/PD 67.2%。
临床怎么用
- 经验性治疗社区获得性呼吸道感染时,应参考当地药敏数据和折点标准选择抗生素。
- 青霉素折点差异大,需根据感染部位和剂量选择解读折点。
- 四环素类、大环内酯类和复方磺胺甲噁唑不宜作为经验性首选。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the antibiotic susceptibility of Streptococcus pneumoniae and Haemophilus influenzae isolates from community-acquired respiratory tract infections (CA-RTIs) collected in 2018-21 from Pakistan. METHODS: MICs were determined by CLSI broth microdilution; susceptibility data were interpreted using CLSI, EUCAST and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. RESULTS: S. pneumoniae (n = 57) and H. influenzae (n = 67) were collected from the Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan. The proportion of penicillin-susceptible pneumococci was 28.1% by CLSI oral/EUCAST low-dose breakpoints; 98.3%/98.2% were susceptible by EUCAST high-dose/CLSI intravenous breakpoints. Good activity (≥93.0%) was observed using CLSI or PK/PD breakpoints for amoxicillin, amoxicillin/clavulanic acid, cefotaxime, cefpodoxime, ceftriaxone, cefuroxime, levofloxacin and moxifloxacin. Cefdinir and cefaclor were less active (75.4% and 57.9%, respectively, by CLSI and 61.4% and 19.3%, respectively, by PK/PD). Tetracyclines, macrolides and trimethoprim/sulfamethoxazole were poorly active (5.3%-36.8%). EUCAST high-dose breakpoints indicated similar activity, although susceptibility to cefaclor (0%), cefpodoxime (70.2%) and cefuroxime (68.4%) was lower than by CLSI. Most H. influenzae isolates were β-lactamase negative (95.5%). Generally, antibiotic susceptibility was >83.6% by CLSI for all antibiotics except trimethoprim/sulfamethoxazole (13.4%). Susceptibility by EUCAST was similar, except for cefuroxime (oral), with 0% susceptible isolates versus 95.5% by CLSI and 67.2% by PK/PD, fluoroquinolones and macrolides (no EUCAST breakpoint). Macrolide susceptibility by PK/PD breakpoints was low. CONCLUSIONS: Although antimicrobial resistance was observed, many therapeutic options remain to treat S. pneumoniae and H. influenzae from CA-RTI in Pakistan despite concerns about high levels of inappropriate antibiotic use. Continued surveillance of antibiotic susceptibility is important for guiding empiric therapy of CA-RTIs.
引用
- Torumkuney D, Nizamuddin S, Morrissey I, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Pakistan: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother. 2025. PMID: 41277338. doi:10.1093/jac/dkaf288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。